{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:15:11Z","timestamp":1791008111338,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,3,9]],"date-time":"2013-03-09T00:00:00Z","timestamp":1362787200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Multiple sclerosis (MS) is a, T cell-mediated autoimmune disease, the management of which remains challenging. The recently described fusion protein, Fn14\u00b7TRAIL, combining the extracellular domain of Fn14 (capable of blocking the pro-inflammatory TWEAK ligand) fused to the extracellular domain of the TRAIL ligand (capable of sending apoptotic signals through its receptors on activated inflammatory cells) was designed to modulate the immune system as an anti-inflammatory agent. The present study explores the efficacy of this purified protein as an anti-inflammatory agent, using the animal model of MS - experimental autoimmune encephalomyelitis (EAE).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>EAE was induced by myelin oligodendrocyte glycoprotein (MOG). Fn14\u00b7TRAIL or vehicle were injected daily for 4 to 16 days, at different time points after disease induction. Animals were examined daily and evaluated for EAE clinical signs. Lymphocytes were analyzed for <jats:italic>ex vivo<\/jats:italic> re-stimulation, cytokine secretion, transcription factor expression and subtype cell analysis. Spinal cords were checked for inflammatory foci. The Mann- Whitney rank sum test, Student\u2019s <jats:italic>t<\/jats:italic>-test or ANOVA were used for statistical analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Significant improvement of EAE in the group treated with Fn14\u00b7TRAIL was noted from day 6 of disease onset and lasted until the end of follow-up (day 40 from disease induction), even in animals treated for 4 days only. Clinical improvement was linked to decreased lymphocyte infiltrates in the central nervous system (CNS) and to decreased Th1 and Th17 responses and to increased number of T- regulatory in the treated mice. No liver or kidney toxicity was evident. <jats:italic>In vitro<\/jats:italic> assays established the ability of Fn14\u00b7TRAIL to induce apoptosis of T cell lines expressing TRAIL receptors and TWEAK.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In this study we established the potency of Fn14\u00b7TRAIL, a unique fusion protein combining two potentially functional domains, in inhibiting the clinical course of EAE, even when given for a short time, without apparent toxicity. These findings make Fn14\u00b7TRAIL a highly promising agent to be used for targeted amelioration of neuro-inflammatory processes, as well as other autoimmune pathologies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1742-2094-10-36","type":"journal-article","created":{"date-parts":[[2013,3,9]],"date-time":"2013-03-09T17:13:52Z","timestamp":1362849232000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Amelioration of autoimmune neuroinflammation by the fusion molecule Fn14\u00b7TRAIL"],"prefix":"10.1186","volume":"10","author":[{"given":"Hodaya","family":"Prinz-Hadad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tehila","family":"Mizrachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Irony-Tur-Sinai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana B","family":"Prigozhina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Aronin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talma","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Dranitzki-Elhalel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,3,9]]},"reference":[{"issue":"Suppl 6","key":"800_CR1_800","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s00415-008-6001-2","volume":"255","author":"T Korn","year":"2008","unstructured":"Korn T: Pathophysiology of multiple sclerosis. \n                           J Neurol 2008,255(Suppl 6):2\u20136.","journal-title":"J Neurol"},{"key":"800_CR2_800","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0896-6273(03)00326-X","volume":"38","author":"SS Zamvil","year":"2003","unstructured":"Zamvil SS, Steinman L: Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis. \n                           Neuron 2003, 38:685\u2013688.","journal-title":"Neuron"},{"key":"800_CR3_800","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nrneurol.2012.168","volume":"8","author":"H Lassmann","year":"2012","unstructured":"Lassmann H, van Horssen J, Mahad D: Progressive multiple sclerosis: pathology and pathogenesis. \n                           Nat Rev Neurol 2012, 8:647\u2013656.","journal-title":"Nat Rev Neurol"},{"key":"800_CR4_800","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/ni0901-762","volume":"2","author":"L Steinman","year":"2001","unstructured":"Steinman L: Multiple sclerosis: a two-stage disease. \n                           Nat Immunol 2001, 2:762\u2013764.","journal-title":"Nat Immunol"},{"key":"800_CR5_800","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/ana.20913","volume":"60","author":"L Steinman","year":"2006","unstructured":"Steinman L, Zamvil SS: How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. \n                           Ann Neurol 2006, 60:12\u201321.","journal-title":"Ann Neurol"},{"key":"800_CR6_800","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.4049\/jimmunol.166.2.1314","volume":"166","author":"B Hilliard","year":"2001","unstructured":"Hilliard B, Wilmen A, Seidel C, Liu TS, Goke R, Chen Y: Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis. \n                           J Immunol 2001, 166:1314\u20131319.","journal-title":"J Immunol"},{"key":"800_CR7_800","doi-asserted-by":"publisher","first-page":"918","DOI":"10.4049\/jimmunol.178.2.918","volume":"178","author":"S Hirata","year":"2007","unstructured":"Hirata S, Matsuyoshi H, Fukuma D, Kurisaki A, Uemura Y, Nishimura Y, Senju S: Involvement of regulatory T cells in the experimental autoimmune encephalomyelitis-preventive effect of dendritic cells expressing myelin oligodendrocyte glycoprotein plus TRAIL. \n                           J Immunol 2007, 178:918\u2013925.","journal-title":"J Immunol"},{"key":"800_CR8_800","doi-asserted-by":"publisher","first-page":"32401","DOI":"10.1074\/jbc.272.51.32401","volume":"272","author":"Y Chicheportiche","year":"1997","unstructured":"Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, Garcia I, Browning JL: TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. \n                           J Biol Chem 1997, 272:32401\u201332410.","journal-title":"J Biol Chem"},{"key":"800_CR9_800","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S0960-9822(98)70204-0","volume":"8","author":"SA Marsters","year":"1998","unstructured":"Marsters SA, Sheridan JP, Pitti RM, Brush J, Goddard A, Ashkenazi A: Identification of a ligand for the death-domain-containing receptor Apo3. \n                           Curr Biol 1998, 8:525\u2013528.","journal-title":"Curr Biol"},{"key":"800_CR10_800","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1084\/jem.192.9.1373","volume":"192","author":"M Nakayama","year":"2000","unstructured":"Nakayama M, Kayagaki N, Yamaguchi N, Okumura K, Yagita H: Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. \n                           J Exp Med 2000, 192:1373\u20131380.","journal-title":"J Exp Med"},{"key":"800_CR11_800","doi-asserted-by":"publisher","first-page":"33166","DOI":"10.1074\/jbc.274.46.33166","volume":"274","author":"RL Meighan-Mantha","year":"1999","unstructured":"Meighan-Mantha RL, Hsu DK, Guo Y, Brown SA, Feng SL, Peifley KA, Alberts GF, Copeland NG, Gilbert DJ, Jenkins NA, Richards CM, Winkles JA: The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. \n                           J Biol Chem 1999, 274:33166\u201333176.","journal-title":"J Biol Chem"},{"key":"800_CR12_800","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S1074-7613(01)00232-1","volume":"15","author":"SR Wiley","year":"2001","unstructured":"Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, Lindner V, Liu H, Daniel TO, Smith CA, Fanslow WC: A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. \n                           Immunity 2001, 15:837\u2013846.","journal-title":"Immunity"},{"key":"800_CR13_800","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/S0006-291X(02)02670-0","volume":"299","author":"N Harada","year":"2002","unstructured":"Harada N, Nakayama M, Nakano H, Fukuchi Y, Yagita H, Okumura K: Pro-inflammatory effect of TWEAK\/Fn14 interaction on human umbilical vein endothelial cells. \n                           Biochem Biophys Res Commun 2002, 299:488\u2013493.","journal-title":"Biochem Biophys Res Commun"},{"key":"800_CR14_800","doi-asserted-by":"publisher","first-page":"8455","DOI":"10.1074\/jbc.274.13.8455","volume":"274","author":"CN Lynch","year":"1999","unstructured":"Lynch CN, Wang YC, Lund JK, Chen YW, Leal JA, Wiley SR: TWEAK induces angiogenesis and proliferation of endothelial cells. \n                           J Biol Chem 1999, 274:8455\u20138459.","journal-title":"J Biol Chem"},{"key":"800_CR15_800","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/S0002-9440(10)63927-2","volume":"162","author":"NL Tran","year":"2003","unstructured":"Tran NL, McDonough WS, Donohue PJ, Winkles JA, Berens TJ, Ross KR, Hoelzinger DB, Beaudry C, Coons SW, Berens ME: The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. \n                           Am J Pathol 2003, 162:1313\u20131321.","journal-title":"Am J Pathol"},{"key":"800_CR16_800","doi-asserted-by":"crossref","first-page":"9675","DOI":"10.1523\/JNEUROSCI.23-29-09675.2003","volume":"23","author":"K Tanabe","year":"2003","unstructured":"Tanabe K, Bonilla I, Winkles JA, Strittmatter SM: Fibroblast growth factor-inducible-14 is induced in axotomized neurons and promotes neurite outgrowth. \n                           J Neurosci 2003, 23:9675\u20139686.","journal-title":"J Neurosci"},{"key":"800_CR17_800","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1242\/jcs.115.2.267","volume":"115","author":"A Jakubowski","year":"2002","unstructured":"Jakubowski A, Browning B, Lukashev M, Sizing I, Thompson JS, Benjamin CD, Hsu YM, Ambrose C, Zheng TS, Burkly LC: Dual role for TWEAK in angiogenic regulation. \n                           J Cell Sci 2002, 115:267\u2013274.","journal-title":"J Cell Sci"},{"key":"800_CR18_800","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/S0165-5728(02)00368-5","volume":"133","author":"S Desplat-Jego","year":"2002","unstructured":"Desplat-Jego S, Varriale S, Creidy R, Terra R, Bernard D, Khrestchatisky M, Izui S, Chicheportiche Y, Boucraut J: TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity. \n                           J Neuroimmunol 2002, 133:116\u2013123.","journal-title":"J Neuroimmunol"},{"key":"800_CR19_800","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jneuroim.2004.10.001","volume":"159","author":"AM Mueller","year":"2005","unstructured":"Mueller AM, Pedre X, Kleiter I, Hornberg M, Steinbrecher A, Giegerich G: Targeting fibroblast growth factor-inducible-14 signaling protects from chronic relapsing experimental autoimmune encephalomyelitis. \n                           J Neuroimmunol 2005, 159:55\u201365.","journal-title":"J Neuroimmunol"},{"key":"800_CR20_800","doi-asserted-by":"publisher","first-page":"460","DOI":"10.2353\/ajpath.2009.080462","volume":"174","author":"M Razmara","year":"2009","unstructured":"Razmara M, Hilliard B, Ziarani AK, Murali R, Yellayi S, Ghazanfar M, Chen YH, Tykocinski ML: Fn14-TRAIL, a chimeric intercellular signal exchanger, attenuates experimental autoimmune encephalomyelitis. \n                           Am J Pathol 2009, 174:460\u2013474.","journal-title":"Am J Pathol"},{"key":"800_CR21_800","doi-asserted-by":"publisher","first-page":"6681","DOI":"10.4049\/jimmunol.0902212","volume":"183","author":"E Nizri","year":"2009","unstructured":"Nizri E, Irony-Tur-Sinai M, Lory O, Orr-Urtreger A, Lavi E, Brenner T: Activation of the cholinergic anti-inflammatory system by nicotine attenuates neuroinflammation via suppression of Th1 and Th17 responses. \n                           J Immunol 2009, 183:6681\u20136688.","journal-title":"J Immunol"},{"key":"800_CR22_800","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.neuropharm.2005.10.013","volume":"50","author":"E Nizri","year":"2006","unstructured":"Nizri E, Hamra-Amitay Y, Sicsic C, Lavon I, Brenner T: Anti-inflammatory properties of cholinergic up-regulation: a new role for acetylcholinesterase inhibitors. \n                           Neuropharmacology 2006, 50:540\u2013547.","journal-title":"Neuropharmacology"},{"key":"800_CR23_800","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.cellimm.2005.11.002","volume":"237","author":"HH Hofstetter","year":"2005","unstructured":"Hofstetter HH, Ibrahim SM, Koczan D, Kruse N, Weishaupt A, Toyka KV, Gold R: Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. \n                           Cell Immunol 2005, 237:123\u2013130.","journal-title":"Cell Immunol"},{"key":"800_CR24_800","doi-asserted-by":"publisher","first-page":"566","DOI":"10.4049\/jimmunol.177.1.566","volume":"177","author":"Y Komiyama","year":"2006","unstructured":"Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S, Sudo K, Iwakura Y: IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. \n                           J Immunol 2006, 177:566\u2013573.","journal-title":"J Immunol"},{"key":"800_CR25_800","doi-asserted-by":"publisher","first-page":"6303","DOI":"10.4049\/jimmunol.164.12.6303","volume":"164","author":"PG Andres","year":"2000","unstructured":"Andres PG, Beck PL, Mizoguchi E, Mizoguchi A, Bhan AK, Dawson T, Kuziel WA, Maeda N, MacDermott RP, Podolsky DK, Reinecker HC: Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis: lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte-associated Th2-type immune response in the intestine. \n                           J Immunol 2000, 164:6303\u20136312.","journal-title":"J Immunol"},{"key":"800_CR26_800","doi-asserted-by":"publisher","first-page":"6873","DOI":"10.1073\/pnas.96.12.6873","volume":"96","author":"KE Balashov","year":"1999","unstructured":"Balashov KE, Rottman JB, Weiner HL, Hancock WW: CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. \n                           Proc Natl Acad Sci USA 1999, 96:6873\u20136878.","journal-title":"Proc Natl Acad Sci USA"},{"key":"800_CR27_800","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.clim.2005.06.005","volume":"117","author":"S Desplat-Jego","year":"2005","unstructured":"Desplat-Jego S, Creidy R, Varriale S, Allaire N, Luo Y, Bernard D, Hahm K, Burkly L, Boucraut J: Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis. \n                           Clin Immunol 2005, 117:15\u201323.","journal-title":"Clin Immunol"},{"key":"800_CR28_800","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.2741\/1395","volume":"9","author":"S Campbell","year":"2004","unstructured":"Campbell S, Michaelson J, Burkly L, Putterman C: The role of TWEAK\/Fn14 in the pathogenesis of inflammation and systemic autoimmunity. \n                           Front Biosci 2004, 9:2273\u20132284.","journal-title":"Front Biosci"},{"key":"800_CR29_800","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jaut.2012.05.003","volume":"39","author":"JS Michaelson","year":"2012","unstructured":"Michaelson JS, Wisniacki N, Burkly LC, Putterman C: Role of TWEAK in lupus nephritis: a bench-to-bedside review. \n                           J Autoimmun 2012, 39:130\u2013142.","journal-title":"J Autoimmun"},{"key":"800_CR30_800","doi-asserted-by":"publisher","first-page":"7949","DOI":"10.4049\/jimmunol.179.11.7949","volume":"179","author":"Z Zhao","year":"2007","unstructured":"Zhao Z, Burkly LC, Campbell S, Schwartz N, Molano A, Choudhury A, Eisenberg RA, Michaelson JS, Putterman C: TWEAK\/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. \n                           J Immunol 2007, 179:7949\u20137958.","journal-title":"J Immunol"},{"key":"800_CR31_800","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1385\/IR:31:2:161","volume":"31","author":"E Cretney","year":"2005","unstructured":"Cretney E, Uldrich AP, Berzins SP, Strasser A, Godfrey DI, Smyth MJ: Are we really on the right TRAIL? \n                           Immunol Res 2005, 31:161\u2013164.","journal-title":"Immunol Res"},{"key":"800_CR32_800","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.neuron.2005.03.018","volume":"46","author":"O Aktas","year":"2005","unstructured":"Aktas O, Smorodchenko A, Brocke S, Infante-Duarte C, Schulze Topphoff U, Vogt J, Prozorovski T, Meier S, Osmanova V, Pohl E, Bechmann I, Nitsch R, Zipp F: Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. \n                           Neuron 2005, 46:421\u2013432.","journal-title":"Neuron"},{"key":"800_CR33_800","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/sj.gt.3302799","volume":"13","author":"Y Jia","year":"2006","unstructured":"Jia Y, Li H, Chen W, Li M, Lv M, Feng P, Hu H, Zhang L: Prevention of murine experimental autoimmune encephalomyelitis by in vivo expression of a novel recombinant immunotoxin DT390-RANTES. \n                           Gene Ther 2006, 13:1351\u20131359.","journal-title":"Gene Ther"},{"key":"800_CR34_800","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s004150200067","volume":"249","author":"TO Jalonen","year":"2002","unstructured":"Jalonen TO, Pulkkinen K, Ukkonen M, Saarela M, Elovaara I: Differential intracellular expression of CCR5 and chemokines in multiple sclerosis subtypes. \n                           J Neurol 2002, 249:576\u2013583.","journal-title":"J Neurol"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1742-2094-10-36.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1742-2094-10-36\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1742-2094-10-36.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T22:35:02Z","timestamp":1630535702000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/1742-2094-10-36"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,9]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["800"],"URL":"https:\/\/doi.org\/10.1186\/1742-2094-10-36","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,9]]},"assertion":[{"value":"25 October 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"800"}}